XVARY Composite Score
31
/ 100
Weak
Combines growth, value, risk, and momentum factors into a single institutional-grade score.
Start here if you're new
What it is
CVD Equipment makes specialized industrial tools for thin-film manufacturing, and it has 118 employees.
How it gets paid
Last year Cvd Equipment made $27M in revenue. Vacuum deposition systems was the main engine at $12.4M, or 46% of sales.
What just happened
Revenue hit $21M, but EPS was still -$0.05.
At a Glance
C++ balance sheet — some cracks in the foundation
20/100 earnings predictability — expect surprises
16.7% return on capital — nothing to write home about
-$0.28 fy2024 eps est
$27M fy2024 rev est
XVARY composite: 31/100 — weak
What They Do
CVD Equipment makes specialized industrial tools for thin-film manufacturing, and it has 118 employees.
You are not buying a fortress here. You are buying a $27M business with $0M of long-term debt and 118 employees. That keeps your downside from turning into a lender problem, but it does not keep customers from walking.
How They Make Money
$27M
annual revenue
Vacuum deposition systems
$12.4M
+181.0%
Service and spares
$6.5M
+8.0%
Process development
$4.1M
+5.0%
Custom components and other
$4.0M
3.0%
The Products That Matter
Manufactures and sells deposition systems
Equipment Sales
$19M · 68% of revenue
This is the core business. It generated $19M last year and grew 11%, so the investment case lives or dies on system demand.
core revenue engine
Service, support, and other revenue
Service & Other
$8M · 32% of revenue
This $8M segment is smaller but steadier in theory. It fell 5%, which matters because a company this size needs every recurring dollar it can keep.
supporting revenue
Key Numbers
$27M
annual revenue
That is the whole top line. On a ~$28M market cap, you are paying about 1x sales.
9.0%
operating margin
This shows the business is still losing money on operations, even with real revenue.
$0M
long-term debt
No long-term debt means lenders are not taking a cut before you do.
29.7%
gross margin
About 30 cents of each sales dollar stays before overhead. That leaves a thin cushion.
Financial Health
C++
Strength
- balance sheet grade C++ — below average — limited financial resources
- risk rank 5 — safer than 5% of stocks
- price stability 5 / 100
- long-term debt $0M (0% of capital)
C++ — below average. watch for debt servicing and cash burn.
Total Return vs. Market
source: institutional data · return history unavailable
What Just Happened
missed estimates
Revenue hit $21M, but EPS was still -$0.05.
Sales were up 181% vs. prior year. Gross margin was 29.7%, so more revenue did not cleanly turn into profit.
$7M
revenue
-$0.05
eps
29.7%
gross margin
the number that mattered
The $21M revenue figure mattered because it jumped 181% vs. prior year, but the -$0.05 EPS shows profit is still fragile.
source: company earnings report, 2025
Get this snapshot in your inbox
This page, delivered free — plus weekly updates when the numbers change. Plain English, no spam.
Weekly updates
Earnings alerts
Plain English
No spam
What Could Go Wrong
The #1 risk is Nasdaq minimum bid price non-compliance. For a $28M company, listing risk is not a side issue — it's the story.
High
Nasdaq listing compliance
The company received a Nasdaq compliance notice in February 2026 for failing to meet the minimum bid price requirement.
If listing status worsens, liquidity and investor access can deteriorate fast.
High
Margin gap versus larger rivals
CVV's Q3 gross margin was 32.7% versus Veeco's 44%. That 11.3-point gap is the cleanest sign that scale and pricing still favor the bigger player.
Lower margins directly limit how much profit this business can produce on just $27M–$28M of revenue.
Med
Backlog conversion risk
The company has $19.4M in backlog, equal to roughly 72% of annual revenue. That's helpful, but backlog is not cash and timing matters.
If orders slip, revenue volatility gets amplified because the business is so small.
Med
Service revenue is shrinking
Service & Other revenue fell 5% to $8M. That's the part of the mix you would normally want acting as ballast.
When the steadier segment weakens, quarterly results become even more dependent on equipment timing.
Between the listing notice, the 11.3-point margin gap, and $19.4M of backlog needing to convert, this is a company with almost no room for execution mistakes.
Source: institutional data · regulatory filings · risk analysis
Pay Attention To
Listing risk
Nasdaq compliance deadline
The minimum bid price issue is existential for a stock this small. If compliance is restored, one major overhang lifts. If not, the market gets much less forgiving.
Margin
Can 32.7% gross margin hold
Q3 showed real improvement from 21.5%. The next report tells you whether that was progress or just one good quarter.
Earnings
Q4 and full-year results
The coming report should show whether backlog is converting into revenue and whether profit can stay above the microscopic levels that make the 81.4x multiple look absurd.
Backlog
$19.4M order backlog
Backlog equal to roughly 72% of annual revenue is the bull case in one number. You want to see it convert, not just sit there.
Analyst Rankings
earnings predictability
20 / 100
In human-speak: quarterly results are hard to trust because a few orders can change everything.
price stability
5 / 100
This stock does not behave like a steady compounder. The $2–$6 52-week range already told you that.
risk rank
5
That places CVV among the market's riskier names. Low debt helps, but tiny scale and weak consistency dominate the profile.
Source: institutional data
Institutional Activity
institutional ownership data for CVV is being compiled.
Source: institutional data
Price Targets
3-5 year target range
$6
Current price
Target midpoint · from current
Want the deeper analysis?
The full deep dive: DCF model, scenario analysis, competitive moat breakdown, and quarterly tracking — everything on this page, taken further.
See plans from $5/moThe Deep Dive